Boström 2018.

Study name	Treatment of Ta bladder cancer in high risk of recurrence—fluorescence cystoscopy with optimized adjuvant mitomycin‐C (FinnBladder 9)
Methods	randomized multicenter/Finland
Participants	Estimated enrollment 400 participants Study setting primary/recurrent only Ta Eligibility criteria number of primary tumors ≥ 2, or size of solitary primary tumor ≥ 3 cm, or recurrent papillary tumors histologically proven Ta bladder cancer histological grade 1 to 2 (WHO 1973 grading system) or PUNLMP or low‐grade (WHO 2004 grading system) bladder cancer Non‐eligibility criteria grade 3 tumors (WHO 1973 grading system) or high‐grade tumors (WHO 2004 grading system) CIS suspicion or evidence of papillary tumors or CIS of the upper urinary tract non‐transitional cell carcinoma suspicion or previous history of the patient not tolerating intravesical instillations known allergy to mitomycin C or hexaminolevulinate
Interventions	No adjuvant instillations Intervention: blue light TURBT with no adjuvant instillations Comparator: white light TURBT with no adjuvant instillations Adjuvant instillations (6 weekly optimized mitomycin C instillations) Intervention: blue light TURBT with adjuvant instillations Comparator: white light TURBT with adjuvant instillations
Outcomes	Primary outcomes  bladder cancer recurrence at 2 years Secondary outcomes  bladder cancer progression to T2 or higher progression, recurrence, or side effects preventing completion of the trial treatment failure (progression, recurrence, or side effects preventing completion of the trial) death due to bladder cancer or other reasons Other outcomes  analysis of cost‐effectiveness
Starting date	August 2012
Contact information	Date of contact attempt to first study author: 28 June 2021 Contact status: reply by author 8 July 2021; study still recruiting; date of anticipated publication 2022 to 2023
Notes	clinicaltrials.gov/ct2/show/NCT01675219